RxDoctor Payments Data

Isam Balat, MD

Obstetrics & Gynecology · Houston, TXNPI 1417914037

Payments from drug & device makers

$3,790in general payments, 2019–2025

Across 203 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$821
  • Sumitomo Pharma America, Inc.$468
  • Myovant Sciences Inc.$325
  • Pfizer$275
  • Mayne Pharma Commercial LLC$186
  • Coopersurgical, Inc.$182
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,773100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,790 in reported general payments places this provider in the 75th percentile of 3,099 obstetrics & gynecology providers in Texas.

See all obstetrics & gynecology providers in Texas

Medicare billing

Part B allowed, 2024
$11,916
Medicare patients
65
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated21$8,249
Estradiol77$2,819
Estradiol (Twice Weekly)Estradiol31$2,494
ValacyclovirValacyclovir Hcl29$910
Terconazole26$761
Clobetasol Propionate45$516
Norethindrone Acetate18$389
Metronidazole31$341
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$310
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet17$302
Fluconazole46$220
Amitriptyline Hcl29$195
Levothyroxine Sodium19$130
ProgesteroneProgesterone, Micronized11$125
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$275$8,24921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,099 obstetrics & gynecology providers in Texas.

Other obstetrics & gynecology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →